Hepatectomy after hepatic arterial therapy with either yttrium-90 or drug-eluting bead chemotherapy: is it safe?

Abstract

Pre-HAT demonstrated similar morbidity, liver-specific morbidity and intra-operative complications when compared with patients undergoing pre-operative chemotherapy alone or without pre-operative chemotherapy. These results suggest that pre-HAT is safe and should not preclude hepatectomy in carefully selected patients.

Contralateral Liver Hypertrophy and Oncological Outcome Following Radioembolization with 90Y-Microspheres: A Systematic Review

“…To date, only a few retrospective clinical series with subsequent hepatic resections following RE are available in the literature, but with favorable oncological and surgical results. [25,49,50]. A time interval of 2 to 3 months between the last RE application and hepatic resection is recommended as optimal timing for resection [51].…”

Locoregional surgical and interventional therapies for advanced colorectal liver metastasis: expert consensus statement

“…Appropriately, and with initial enthusiasm, the authors mention the continued evaluation of the use of intra‐arterial therapies to downsize metastasis . A large amount of safety data derived from patients who have undergone hepatectomy following yttrium‐90 radioembolization and drug‐eluting bead therapy or a combination of these is available from a number of high‐volume institutions . Hepatectomy performed at least 4–6 months after radioembolization or drug‐eluting bead therapy appears to be safe.…”

“…Hepatectomy performed at least 4–6 months after radioembolization or drug‐eluting bead therapy appears to be safe. Similarly, hepatectomy after prior intra‐arterial therapy appears to be safe . Thus, patients in whom disease has been downsized by such intra‐arterial therapies should undergo evaluation for surgical treatment of all known disease.…”

Combined pancreas and liver therapies: Resection and ablation in hepato‐pancreatico‐biliary malignancies

“…Perioperative complications were graded on a five‐point scale 17, 18. This study included 21 patients presenting with at least one of the following disease histologies: neuroendocrine (8), carcinoid (1), gallbladder cancer (2), colorectal metastasis (4), cholangiocarinoma (1), mucinous pancreatic tumor (1), pancreatic adenocarcinoma (2), ovarian (1), renal cell carcinoma (1), diffuse large B‐cell lymphoma (1).…”